ImmuneBridge Revenue and Competitors

Location

#4020

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • ImmuneBridge's estimated annual revenue is currently $2.6M per year.(i)
  • ImmuneBridge's estimated revenue per employee is $77,500
  • ImmuneBridge's total funding is $12M.

Employee Data

  • ImmuneBridge has 34 Employees.(i)
  • ImmuneBridge grew their employee count by 89% last year.

ImmuneBridge's People

NameTitleEmail/Phone
1
Co-founder and CEOReveal Email/Phone
2
Chief Staff & Head OperationsReveal Email/Phone
3
Head ProductReveal Email/Phone
4
Head Research - NK TherapeuticsReveal Email/Phone
5
VP CMCReveal Email/Phone
6
Office ManagerReveal Email/Phone
7
ImmunologistReveal Email/Phone
8
Senior ScientistReveal Email/Phone
9
Scientist, Process Development Cell TherapyReveal Email/Phone
10
Associate ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is ImmuneBridge?

ImmuneBridge is developing allogeneic immunotherapies for cancer. Our core technology drives the expansion of cord blood derived immune stem cells and establishes a novel, flexible, consistent and abundant cellular source for immunotherapies. We are currently pursuing natural killer cell products for hematological malignancies. Next we will use the unique advantages of our cellular source to tackle solid tumors.\n\nPlatform\n\nImmuneBridge is creating a platform of scalable allogeneic immune cell therapies from cord blood. Our proprietary technology, including a novel small molecule, expands cord blood HSPCs over 100,000-fold while maintaining full immune multipotency, with the ability to differentiate into cell types including NK cells, T cells and macrophages.\n\nPipeline\n\nIn the near term, our goal is to validate the economic and clinical benefits of our expansion technology by taking an expanded-HSC-derived NK cell to clinical trials for hematological malignancies. In the long term, our unique access to the modified and unmodified immune tree allows us to tackle the challenge of solid tumors with combinations of modified cells.\n\nAgile Discovery\n\nThis agile and flexible allogeneic platform reduces costs of discovery and manufacturing, expanding commercially viable indications for cellular immunotherapy. Starting from cord blood has speed and cost advantages over iPSCs, including the ability to quickly match HLA types to target populations or select beneficial genotypes without the need to edit those features into a clonal iPS line. This enables rapid iterations of abundant and consistent sources of therapeutic cells.

keywords:N/A

$12M

Total Funding

34

Number of Employees

$2.6M

Revenue (est)

89%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.6M34-19%$14.2M
#2
$3.6M3417%$44M
#3
$3.9M34N/AN/A
#4
$3.6M340%$11.4M
#5
$3.8M34N/AN/A